A new benchtop automated reading and incubation system for antimicrobial susceptibility testing (AST) enables microbiology laboratories with accurate MIC results that clinicians need to confidently select an effective antibiotic for critically ill patients while safeguarding future patient care through more successful antimicrobial stewardship.
Backed by a long history of AST accuracy, the Thermo Scientific Sensititre ARIS HiQ AST System relies on broth microdilution to provide an MIC result that supports the optimization of treatment decisions and ultimately, patient outcomes.
Thermo Fisher Scientific previewed the Sensititre ARIS HiQ AST System during the 71st American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2019), that was held August 4–8 at the Anaheim Convention Center in California.
The new system adds value to laboratories that routinely retest invalid AST results or that require additional confirmatory testing prior to releasing results to clinicians. The immediate accuracy of phenotypically-driven MIC values delivers reliable results while minimizing re-tests, and can support a reduction in hidden costs associated with reporting delays.
Through close collaboration with pharmaceutical companies, the Sensititre ARIS HiQ AST System also offers wide and up-to-date selections of antimicrobials, enabling earlier access to the latest therapies for multidrug-resistant infections. In addition, laboratories can create their own custom AST plates from a selection of over 300 antimicrobials in broad dilution ranges to consolidate and reduce offline testing.
The Sensititre ARIS HiQ AST System has an expanded capacity of up to 100 Sensititre plates in a limited footprint that makes it possible to process more tests at one time while conserving valuable bench space. It also features an intuitive touchscreen user interface for convenient operation; 24/7 access to critical test information; and batch load and unload capability for improved testing workflow.